Neoadjuvant Chemoradiotherapy Plus Sintilimab for Intermediate/High Immunoscore Locally Advanced Rectal Cancer
Status:
Recruiting
Trial end date:
2027-01-01
Target enrollment:
Participant gender:
Summary
Immunoscore has been reported to be superior to microsatellite instability staging in
predicting the disease-specific recurrence and survival for patients with colorectal cancer.
However, the relationship between Immunoscore and its impact on patient's response to PD-1
blockade remains to be elucidated. This phase II, prospective, open label study is designed
to evaluate the efficacy and safety of combination neoadjuvant chemoradiotherapy (nCRT) with
the anti-PD-1 antibody sintilimab for intermediate/high Immunoscore locally advanced rectal
cancer.